Undisclosed c-MET degrading EpiTAC / EpiBiologics - LARVOL DELTA

Dual modality of EpiTAC bispecific degrader ADCs combines c-MET degradation with cytotoxic payload delivery to overcome limitations of current c-MET-targeted therapies (AACR 2026) - "This approach has the potential to address oncogenic driver and resistance mechanisms broadly across cMET-driven tumors. In addition to targeting cMET-high tumors, EpiTAC-ADCs have the potential to target low and medium cMET tumors in patients whose needs are not addressed by standard of care therapeutics including ADCs."

ADC • Bispecific • Oncology • MET

Discovery of c-MET degrading bispecific antibodies (EpiTACs) for NSCLC and other c-MET driven tumors (AACR 2025) - "These newly discovered degraders are being paired with novel c-MET binders that lack dimerization-induced signaling capacity, to create safer and more efficacious c-MET degrading therapeutics. In conclusion, eTPD represents a promising new drug modality, and EpiTACs have expanded the toolbox of extracellular targeted protein degraders to address challenging drug targets with a new approach."

Bispecific • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody (Businesswire) - "Key highlights of EpiBiologics’ data include: c-Met EpiTACs degraded oncogenic mutant and wildtype forms of c-Met on tumor cells and demonstrated sustained tumor growth suppression in a patient-derived mouse model of NSCLC; Degradation of c-Met resulted in deep anti-tumor activity, driven by the ability of EpiTACs to remove the oncogenic protein and associated scaffolding; Combining targeted protein degradation of c-Met with a cytotoxic ADC payload suppressed tumor growth in c-Met-mutant, c-Met-amplified, and c-Met-overexpressed tumors, potentially broadening the clinical opportunity into tumors that have low c-Met expression and are not solely dependent on c-Met signaling for survival."

Preclinical • Oncology